Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Investor contacts Jenna Cohen Vice President, Investor Relations & Global Business Communications 857.209.3147
Cassie SaitowDirector, Investor Relations 617.909.3127
ir@blueprintmedicines.com
Media contacts Andrew Law Senior Director, Global Business Communications 617.844.8205
Jessica Mullan Director, Corporate Communications 857.260.0058
media@blueprintmedicines.com

SEC Filings

Filing date	Form	Description	View
Mar 23, 2015	CORRESP	CORRESP	View HTML 0001104659-15-021789.pdf 0001104659-15-021789.rtf 0001104659-15-021789.xls
Mar 20, 2015	UPLOAD	UPLOAD	View HTML 0000000000-15-016713.pdf
Mar 16, 2015	DRS/A	mendment to a previously filed DRS	View HTML 0000912057-15-000057.pdf 0000912057-15-000057.rtf 0000912057-15-000057.xls
Feb 19, 2015	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	View HTML 0000912057-15-000045.pdf 0000912057-15-000045.rtf 0000912057-15-000045.xls
Nov 20, 2014	D		View HTML 0001597264-14-000002.pdf 0001597264-14-000002.rtf 0001597264-14-000002.xls
Jan 17, 2014	D		View HTML 0001597264-14-000001.pdf 0001597264-14-000001.rtf 0001597264-14-000001.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

SEC Filings

Pagination